Prime Medicine ($PRME) Stock Forecast: Down 5.0% Today

What is Prime Medicine?

Prime Medicine (NASDAQ: PRME) operates in the biotech sector, primarily working on developing CRISPR-derived prime editing therapies for genetic disorders. The stock experienced a decrease in value today.

Why is Prime Medicine going down?

PRME stock is down 5.0% on Dec 24, 2025 14:40

• Despite falling short of projected quarterly EPS and showing minimal revenue, an upgrade to a "strong-buy" rating by Lifesci Capital could have led to initial investor optimism.
• Nevertheless, the company's notable negative margins and return on equity, combined with other entities issuing "sell" recommendations, may have fueled increased selling activity and the downward movement in the stock price.
• Speculation arose among investors due to the CEO hinting at a shift in focus towards larger opportunities in different diseases, potentially contributing to the uncertainty surrounding the stock and its decline.
• The fluctuating opinions of analysts, the company's strategic adjustments, and its financial performance likely played a crucial role in the bearish trend witnessed in PRME's market performance for the day.

PRME Price Chart

PRME Technical Analysis

PRME News

Prime Medicine (NASDAQ:PRME) Upgraded at Lifesci Capital

Lifesci Capital upgraded Prime Medicine (NASDAQ:PRME) to a "strong-buy" rating, despite the company missing quarterly EPS estimates, posting low revenue, and having significant negative margins and return on equity. The stock opened at $3.69 with a 52-week range of $1.11–$6.94 and a market cap of approximately $666 million. Other firms have issued "sell" ratings, and the overall consensus from MarketBeat is a "Moderate Buy."

https://www.marketbeat.com/instant-alerts/prime-medicine-nasdaqprme-upgraded-at-lifesci-capital-2025-12-24/

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by Brokerages

Prime Medicine, Inc. (NYSE:PRME) has received a consensus "Moderate Buy" rating from six brokerages, with three analysts recommending "hold" and three recommending "buy." The average 12-month price target is $7.45, although recent adjustments include Chardan cutting its target to $9, Wedbush at $8, and Citi lowering its target to $4.25. Institutional investors hold 70.37% of the stock, and the company focuses on developing CRISPR-derived prime editing therapies for various genetic disorders.

https://www.marketbeat.com/instant-alerts/prime-medicine-inc-nyseprme-given-consensus-rating-of-moderate-buy-by-brokerages-2025-12-21/

Asked and Answered: Prime Medicine CEO on First Prime Editing Patient Data

Prime Medicine CEO Allan Reine discusses the implications of promising initial patient data from a prime editing treatment for chronic granulomatous disease (CGD) on the company's clinical roadmap. Despite the success, Prime Medicine is pausing active recruitment for the CGD trial due to market size, redirecting focus to larger opportunities in liver, lung diseases, and immune-system cancers, while actively pursuing collaborations and advancements in prime editing technology. Reine emphasizes the goal of expanding prime editing's reach to more diseases and patients through strategic resource allocation and partnerships.

https://www.insideprecisionmedicine.com/topics/precision-medicine/asked-and-answered-prime-medicine-ceo-on-first-prime-editing-patient-data/

Trending Today

Marsh & McLennan Companies Inc. ($MMC) Stock Forecast: Down 0.3% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.3% Today

Nike Inc. ($NKE) Stock Forecast: Up 5.3% Today

Groupon Inc. ($GRPN) Stock Forecast: Up 5.0% Today

Hologic Inc. ($HOLX) Stock Forecast: Down 0.6% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.3% Today

FuelCell Energy ($FCEL) Stock Forecast: Down 6.1% Today

Prime Medicine ($PRME) Stock Forecast: Down 5.0% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 5.7% Today

Bittensor ($TAO) Crypto Forecast: Down 5.1% Today

Prime Medicine Price History

28.10.2025 - PRME Stock was up 5.1%

• Prime Medicine's announcement of their participation in the 8th Annual Evercore Healthcare Conference likely sparked investor interest and confidence in the company's future prospects.
• The market responded positively to the potential of Prime Medicine's differentiated genetic therapies, indicating optimism about the company's ability to revolutionize the biotechnology industry.
• Investor sentiment was likely bolstered by the leadership of Allan Reine, M.D., the Chief Executive Officer of Prime Medicine, further contributing to the bullish movement in PRME stock today.

15.11.2025 - PRME Stock was down 5.4%

• The bearish movement in PRME's stock today can be attributed to the fact that despite a recent 28% rise in stock value, the company's shares are still trading below the 50-day simple moving average. This indicates a potential lack of sustained momentum in the stock price.
• The negative sentiment from Wall Street analysts, who have issued "sell" ratings due to weak fundamentals such as an EPS miss and negative net margin, could have contributed to the downward pressure on PRME's stock.
• Despite the positive news of successful clinical trial results for PM359, a gene therapy for Chronic Granulomatous Disease, the market may be reacting cautiously due to the inherent regulatory scrutiny and market volatility associated with the gene therapy sector.
• The significant increase in market capitalization following insider stock buying might have initially boosted investor confidence, but ongoing concerns about the company's financial health and overall market conditions could be tempering the stock's performance.

04.07.2025 - PRME Stock was up 6.7%

• Prime Medicine Inc. (PRME) experienced a strong bullish movement today.
• The bullish momentum can be attributed to the successful closing of a public offering and the full exercise of the underwriters' option to purchase additional shares, indicating strong investor interest and confidence in the company's future prospects.
• The company's focus on delivering a new class of differentiated one-time curative genetic therapies seems to have resonated well with investors, leading to increased buying activity.
• The stock trading above the golden cross further reinforces positive sentiment and may attract more investors looking for potential buying opportunities in PRME.

15.08.2025 - PRME Stock was down 5.7%

• Cathie Wood's Ark Invest reducing its holdings in a popular AI stock might have triggered worries among investors about the sector's growth outlook.
• A notable transaction involving Tempus AI Inc could have prompted uncertainties about the company's future results, potentially causing a decline in related AI stocks like PRME.
• Investors' response to these developments may have led to the selling of PRME shares, influencing the stock's bearish performance today.

07.07.2025 - PRME Stock was down 8.0%

• PRME reported a Q2 loss and missed revenue estimates, signaling potential financial challenges ahead.
• The announcement of the closing of a public offering and the full exercise of underwriters' option to purchase additional shares might have led to dilution concerns among investors, contributing to the bearish movement.
• The market may be reacting negatively to the company's financial performance and the implications of the recent public offering on its future earnings potential.
• Investors could be cautious about PRME's ability to execute its strategic plans effectively in the competitive biotechnology industry, leading to a decline in the stock price.

10.11.2025 - PRME Stock was down 5.0%

• Despite positive results from successful Phase 1/2 clinical trials for PM359 and its publication in renowned journals, the stock witnessed a downward trend.
• This downturn may have been triggered by investors cashing out profits after significant market capitalization growth and favorable clinical data.
• The bearish movement could also be linked to general market instability or external factors affecting the broader biotech industry.
• It is essential to bear in mind that short-term stock price fluctuations may not accurately depict the long-term promise of Prime Medicine's groundbreaking gene editing technologies.

11.11.2025 - PRME Stock was up 5.3%

• PRME's market capitalization increased by US$161 million, with a 28% rise in stock value, driven by a year of insider stock buying. The CEO and other insiders' significant purchases at lower prices reflect confidence in the company's undervaluation and future prospects.
• The positive stock movement was also influenced by the successful Phase 1/2 clinical trial results for PM359, a gene therapy for Chronic Granulomatous Disease, published in prestigious journals revealing the company's scientific breakthroughs and potential for long-term growth.
• The high insider ownership of 15% and the significant R&D investment by Prime Medicine indicate a strong foundation for future success, despite challenges in the gene therapy sector such as regulatory scrutiny and market volatility.
• Overall, the combination of insider confidence through stock purchases, successful clinical trial results, and positive publications contributed to PRME's bullish market movement, highlighting investor optimism in the company's innovative approach to gene therapy.

08.11.2025 - PRME Stock was up 5.3%

• PRME stock surged following the announcement of Phase 1/2 clinical data for PM359. The data, published in a medical journal, showcased promising results for the treatment of chronic granulomatous disease (CGD).
• The positive data highlighted the potential of Prime Editing technology as a precise and safe therapeutic strategy for CGD, with findings including rapid neutrophil engraftment and no significant adverse events.
• Investors reacted favorably to the news, driving the bullish movement in PRME stock as they anticipate the future commercialization and success of PM359 in the gene therapy market.
• The strong performance of PRME today contrasts with its recent financial struggles, as reflected in the Q1 loss and revenue miss. This indicates that positive clinical developments can quickly shift market sentiment towards a biotech company.

07.10.2025 - PRME Stock was down 13.7%

• PRME disclosed third-quarter financial figures, showcasing a substantial loss and revenue below expectations, resulting in a pessimistic investor outlook.
• Despite appointing a new Chief Business Officer, apprehensions regarding the company's financial standings persisted.
• The market's response might be tied to delays in seeking regulatory approvals for PM577 in Wilson's Disease, impacting confidence in PRME's product lineup and future prospects.
• In summary, the unsatisfactory financial performance coupled with potential setbacks in crucial projects likely contributed to the stock's bearish trend.

07.10.2025 - PRME Stock was down 10.5%

• PRME reported a Q3 loss and missed revenue estimates by a significant margin, leading to investor concerns about the company's financial performance.
• The appointment of a new Chief Business Officer may have initially been seen as a positive move, but the market reaction suggests that investors are more focused on the company's financial health.
• The disappointing financial results indicate potential challenges in the company's operations or market acceptance of its therapies, contributing to the bearish movement in PRME's stock price.
• Investors may be cautious about PRME's future prospects until there is more clarity on its ability to improve financial performance and deliver on its promise of innovative genetic therapies.

24.11.2025 - PRME Stock was down 5.0%

• Despite falling short of projected quarterly EPS and showing minimal revenue, an upgrade to a "strong-buy" rating by Lifesci Capital could have led to initial investor optimism.
• Nevertheless, the company's notable negative margins and return on equity, combined with other entities issuing "sell" recommendations, may have fueled increased selling activity and the downward movement in the stock price.
• Speculation arose among investors due to the CEO hinting at a shift in focus towards larger opportunities in different diseases, potentially contributing to the uncertainty surrounding the stock and its decline.
• The fluctuating opinions of analysts, the company's strategic adjustments, and its financial performance likely played a crucial role in the bearish trend witnessed in PRME's market performance for the day.

03.10.2025 - PRME Stock was down 5.9%

• The recent hiring of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer may have fallen short of investor expectations, resulting in a lack of confidence in the company's strategic course.
• Concerns may arise among investors regarding how this appointment could influence Prime Medicine's current projects and future growth opportunities.
• The market's response suggests doubt or hesitation about the company's ability to fulfill its commitment to innovative genetic treatments, generating a pessimistic outlook among investors.